



## Clinical trial results:

**A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study with an Optional Safety Extension Treatment Period up to 6 months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting 2 Agonists (LABA), in Patients with Uncontrolled Persistent Asthma**

### Summary

EudraCT number	2012-001869-33
Trial protocol	GB DE CZ HU PL SK BG
Global end of trial date	19 December 2014

### Results information

Result version number	v1 (current)
This version publication date	21 February 2016
First version publication date	21 February 2016

### Trial information

#### Trial identification

Sponsor protocol code	D3551C00001
-----------------------	-------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	Pepparedsleden 1, Mölndal, Sweden, SE-431 83
Public contact	Bengt Larsson, AstraZeneca, SE-431 83 +46 31 7064277, bengt.larsson@astrazeneca.com
Scientific contact	Paul O'Byrne, St Joseph's Healthcare, L8N 4A6 9055259140-33694, obyrdnep@mcmaster.ca

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 December 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	19 December 2014
Global end of trial reached?	Yes
Global end of trial date	19 December 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To determine the efficacy of 3 different doses of AZD5069 compared with placebo on the rate of severe asthma exacerbations over 6 months in adults with uncontrolled persistent asthma, despite treatment with medium to high dose ICS ( $\geq$ fluticasone 500  $\mu$ g or the equivalent daily) and LABA

Protection of trial subjects:

This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) and applicable regulatory requirements and the AstraZeneca policy on Bioethics and Human Biological Samples.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	27 November 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Bulgaria: 121
Country: Number of subjects enrolled	Poland: 114
Country: Number of subjects enrolled	Russian Federation: 87
Country: Number of subjects enrolled	Ukraine: 65
Country: Number of subjects enrolled	Hungary: 55
Country: Number of subjects enrolled	Romania: 50
Country: Number of subjects enrolled	Mexico: 37
Country: Number of subjects enrolled	Slovakia: 36
Country: Number of subjects enrolled	Germany: 30
Country: Number of subjects enrolled	Czech Republic: 29
Country: Number of subjects enrolled	South Africa: 11
Country: Number of subjects enrolled	Canada: 5
Worldwide total number of subjects	640
EEA total number of subjects	435

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	544
From 65 to 84 years	96
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

First patient enrolled: 27 November 2012 . Last patient last visit: 27 August 2014. Twelve centres across 12 countries participated in this study: Denmark (4), Germany (13), Poland (6), Russia (14), Sweden(13)and United Kingdom (5)

### Pre-assignment

Screening details:

1146 patients enrolled in the study of which 640 were randomised, the remaining 506 patients were not randomised since they did not fulfilled all the inclusion conditions.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

### Arms

Are arms mutually exclusive?	No
<b>Arm title</b>	AZD 5069 5mg

Arm description: -

Arm type	Experimental
Investigational medicinal product name	AZD 5069
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

5mg capsule BID

<b>Arm title</b>	AZD 5069 15 mg
------------------	----------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	AZD 5069
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

capsule 15mg, twice a day

<b>Arm title</b>	AZD5069 45mg
------------------	--------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	AZD 5069
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Capsules twice a day

<b>Arm title</b>	Placebo
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

capsule to match AZD5069

<b>Number of subjects in period 1</b>	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg
Started	160	156	162
Completed	145	143	145
Not completed	15	13	17
Adverse event, serious fatal	-	-	1
Eligibility criteria not fulfilled	6	3	2
Subject decision	6	5	8
Adverse event, non-fatal	-	2	5
Development of study specific withdrawal criteria	1	-	1
unknown reason for study withdrawn	1	1	-
Protocol deviation	1	2	-

<b>Number of subjects in period 1</b>	Placebo
Started	162
Completed	151
Not completed	11
Adverse event, serious fatal	-
Eligibility criteria not fulfilled	3
Subject decision	4
Adverse event, non-fatal	4
Development of study specific withdrawal criteria	-
unknown reason for study withdrawn	-
Protocol deviation	-

## Baseline characteristics

### Reporting groups

Reporting group title	AZD 5069 5mg
Reporting group description: -	
Reporting group title	AZD 5069 15 mg
Reporting group description: -	
Reporting group title	AZD5069 45mg
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Reporting group values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg
Number of subjects	160	156	162
Age Categorical Units: Subjects			
≥18 - <50	64	57	68
≥50 - <65	72	79	74
≥65	24	20	20
Age Continuous Units: years			
arithmetic mean	53	52	51
standard deviation	± 11.5	± 12.7	± 11.6
Gender Categorical Units: Subjects			
Female	104	113	107
Male	56	43	55

Reporting group values	Placebo	Total	
Number of subjects	162	640	
Age Categorical Units: Subjects			
≥18 - <50	48	237	
≥50 - <65	82	307	
≥65	32	96	
Age Continuous Units: years			
arithmetic mean	54	-	
standard deviation	± 11.1		
Gender Categorical Units: Subjects			
Female	120	444	
Male	42	196	

### Subject analysis sets

Subject analysis set title	Full analysis set
Subject analysis set type	Full analysis

Subject analysis set description:

All patients randomised to investigational product were included in the full analysis set (FAS), irrespective of their protocol adherence and continued participation in the study. Patients were analysed according to their randomised investigational product irrespective of whether or not they prematurely discontinued investigational product or administered the incorrect treatment. Patients who withdrew consent to participate in the study were included up to the date of their study termination.

Reporting group values	Full analysis set		
Number of subjects	640		
Age Categorical			
Units: Subjects			
≥18 - <50	237		
≥50 - <65	307		
≥65	96		
Age Continuous			
Units: years			
arithmetic mean	52		
standard deviation	± 11.8		
Gender Categorical			
Units: Subjects			
Female			
Male			

## End points

### End points reporting groups

Reporting group title	AZD 5069 5mg
Reporting group description: -	
Reporting group title	AZD 5069 15 mg
Reporting group description: -	
Reporting group title	AZD5069 45mg
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	
Subject analysis set title	Full analysis set
Subject analysis set type	Full analysis

Subject analysis set description:

All patients randomised to investigational product were included in the full analysis set (FAS), irrespective of their protocol adherence and continued participation in the study. Patients were analysed according to their randomised investigational product irrespective of whether or not they prematurely discontinued investigational product or administered the incorrect treatment. Patients who withdrew consent to participate in the study were included up to the date of their study termination.

### Primary: number of severe exacerbations over 6 months

End point title	number of severe exacerbations over 6 months
End point description:	
End point type	Primary
End point timeframe:	
6 months	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	161	159
Units: number				
number (not applicable)	28	33	35	25

### Statistical analyses

Statistical analysis title	Analysis of the rate of severe exacerbations
Statistical analysis description:	
Primary Analysis Model: Rates, rate ratios and p-values are from a Poisson regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model.	
Comparison groups	AZD5069 45mg v Placebo



Number of subjects included in analysis	320
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.119
Method	poission regression
Parameter estimate	Risk ratio (RR)
Point estimate	1.56
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.98
upper limit	2.49

<b>Statistical analysis title</b>	Analysis of the rate of severe exacerbations
-----------------------------------	--

Statistical analysis description:

Primary Analysis Model: Rates, rate ratios and p-values are from a Poisson regression analysis with treatment, OCS use at baseline (yes or no),geographical region and FEV1 pre-bronchodilator at baseline included in the model.

Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.141
Method	poission regression
Parameter estimate	Risk ratio (RR)
Point estimate	1.53
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.95
upper limit	2.46

<b>Statistical analysis title</b>	Analysis of the rate of severe exacerbations
-----------------------------------	--

Statistical analysis description:

Primary Analysis Model: Rates, rate ratios and p-values are from a Poisson regression analysis with treatment, OCS use at baseline (yes or no),geographical region and FEV1 pre-bronchodilator at baseline included in the model.

Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.397
Method	poission resgrssion
Parameter estimate	Risk ratio (RR)
Point estimate	1.29

Confidence interval	
level	90 %
sides	2-sided
lower limit	0.79
upper limit	2.11

### Primary: total number of days of severe exacerbation

End point title	total number of days of severe exacerbation
End point description:	
End point type	Primary
End point timeframe:	
over 6 months	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	161	159
Units: days				
number (not applicable)	255	271	291	220

### Statistical analyses

Statistical analysis title	total number of days of severe exacerbation
Statistical analysis description:	
Estimates, ratios and p-values are from a negative binomial regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.111
Method	negative binomial regression
Parameter estimate	Risk ratio (RR)
Point estimate	1.64
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.98
upper limit	2.74

<b>Statistical analysis title</b>	total number of days of severe exacerbation
Statistical analysis description:	
Estimates, ratios and p-values are from a negative binomial regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.191
Method	negative binomial regression
Parameter estimate	Risk ratio (RR)
Point estimate	1.52
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.9
upper limit	2.58

<b>Statistical analysis title</b>	total number of days of severe exacerbation
Statistical analysis description:	
Estimates, ratios and p-values are from a negative binomial regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model.	
Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	320
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.123
Method	negative binomial regression
Parameter estimate	Risk ratio (RR)
Point estimate	1.62
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.97
upper limit	2.7

<b>Primary: Patients experiencing one or more severe exacerbations</b>	
End point title	Patients experiencing one or more severe exacerbations
End point description:	
End point type	Primary
End point timeframe:	
over 6 months	

<b>End point values</b>	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	161	159
Units: participants				
number (not applicable)	23	26	28	21

## Statistical analyses

<b>Statistical analysis title</b>	experiencing one or more severe exacerbations
Statistical analysis description: logistic regression analysis with treatment, OCS use at baseline (yes or no) and geographical region included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.627
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.17
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.68
upper limit	2.02

<b>Statistical analysis title</b>	experiencing one or more severe exacerbations
Statistical analysis description: logistic regression analysis with treatment, OCS use at baseline (yes or no) and geographical region included in the model	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.296
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.82
upper limit	2.38

<b>Statistical analysis title</b>	experiencing one or more severe exacerbations
Statistical analysis description: logistic regression analysis with treatment, OCS use at baseline (yes or no) and geographical region included in the model	
Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	320
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.261
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.43
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.85
upper limit	2.41

## Secondary: event of asthma-specific hospital/intensive care unit (ICU)admissions

End point title	event of asthma-specific hospital/intensive care unit (ICU)admissions
End point description:	
End point type	Secondary
End point timeframe: over 6 months	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	161	159
Units: events				
number (not applicable)	2	2	4	3

## Statistical analyses

<b>Statistical analysis title</b>	rate of asthma-specific hospital(ICU) admissions
Statistical analysis description: Poisson regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model.	
Comparison groups	AZD 5069 5mg v Placebo

Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.806
Method	Poisson regression
Parameter estimate	Risk ratio (RR)
Point estimate	0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.17
upper limit	3.63

<b>Statistical analysis title</b>	rate of asthma-specific hospital(ICU) admissions
-----------------------------------	--

Statistical analysis description:

Poisson regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model

Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.844
Method	Poisson regression
Parameter estimate	Risk ratio (RR)
Point estimate	0.83
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.18
upper limit	3.8

<b>Statistical analysis title</b>	rate of asthma-specific hospital (ICU) admissions
-----------------------------------	---

Statistical analysis description:

Poisson regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	320
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.563
Method	Poisson regression
Parameter estimate	Risk ratio (RR)
Point estimate	1.56

Confidence interval	
level	90 %
sides	2-sided
lower limit	0.44
upper limit	5.59

## Secondary: total number of days of asthma-specific hospital /intensive care unit (ICU) admissions

End point title	total number of days of asthma-specific hospital /intensive care unit (ICU) admissions
End point description:	
End point type	Secondary
End point timeframe: over 6 months	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	161	159
Units: days				
number (not applicable)	9	49	53	57

## Statistical analyses

<b>Statistical analysis title</b>	days of asthma-specific hospital (ICU) admissions
Statistical analysis description: negative binomial regression analysis with treatment,OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0
Method	negative binomial regression
Parameter estimate	Risk ratio (RR)
Point estimate	0.02
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.01
upper limit	0.07

<b>Statistical analysis title</b>	days of asthma-specific hospital(ICU) admissions
Statistical analysis description: negative binomial regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0
Method	negative binomial regression
Parameter estimate	Risk ratio (RR)
Point estimate	9.62
Confidence interval	
level	90 %
sides	2-sided
lower limit	5.06
upper limit	18.28

<b>Statistical analysis title</b>	days of asthma-specific hospital(ICU) admissions
Statistical analysis description: negative binomial regression analysis with treatment,OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model.	
Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	320
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0
Method	negative binomial regression
Parameter estimate	Risk ratio (RR)
Point estimate	6.37
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.38
upper limit	11.97

<b>Secondary: total number of days of oral corticosteroids (OCS) use due to worsening in asthma symptoms</b>	
End point title	total number of days of oral corticosteroids (OCS) use due to worsening in asthma symptoms
End point description:	
End point type	Secondary
End point timeframe: over 6 months	



<b>End point values</b>	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	161	159
Units: days				
number (not applicable)	247	227	266	183

## Statistical analyses

<b>Statistical analysis title</b>	days of OCS uses
Statistical analysis description: negative binomial regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.067
Method	negative binomial regression
Parameter estimate	Risk ratio (RR)
Point estimate	1.77
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.06
upper limit	2.95

<b>Statistical analysis title</b>	days of OCS use
Statistical analysis description: negative binomial regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.164
Method	negative binomial regression
Parameter estimate	Risk ratio (RR)
Point estimate	1.57

Confidence interval	
level	90 %
sides	2-sided
lower limit	0.92
upper limit	2.66

<b>Statistical analysis title</b>	days of OCS use
-----------------------------------	-----------------

Statistical analysis description:

negative binomial regression analysis with treatment, OCS use at baseline (yes or no), geographical region and FEV1 pre-bronchodilator at baseline included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	320
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.172
Method	negative binomial regression
Parameter estimate	Risk ratio (RR)
Point estimate	1.54
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.92
upper limit	2.58

## Secondary: Pre-bronchodilator FEV1, measured before the morning administration of the investigational product

End point title	Pre-bronchodilator FEV1, measured before the morning administration of the investigational product
-----------------	--

End point description:

Baseline is defined as the latest non-missing assessment prior to first dose (typically Visit 2, Randomisation). Treatment Period is defined as the average change from baseline across all available visits during the 6-month double-blind treatment period regardless of whether or not a patient was actually taking IP at that visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and post treatment

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	155	151	159	158
Units: liter				
least squares mean (standard error)	0.07 (± 0.037)	0.08 (± 0.037)	0.11 (± 0.036)	0.09 (± 0.036)

## Statistical analyses

<b>Statistical analysis title</b>	FEV1 pre-bronchodilator
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	313
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.601
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.02
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.08
upper limit	0.04

<b>Statistical analysis title</b>	FEV1 pre-bronchodilator
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	309
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.884
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.01
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.06
upper limit	0.05

<b>Statistical analysis title</b>	FEV1 pre-bronchodilator
-----------------------------------	-------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	317
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.47
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.03
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.03
upper limit	0.08

### Secondary: Post-bronchodilator FEV1, measured before the morning administration of the investigational product

End point title	Post-bronchodilator FEV1, measured before the morning administration of the investigational product
-----------------	---

End point description:

Baseline is defined as the latest non-missing assessment prior to first dose (typically Visit 2, Randomisation). Treatment Period is defined as the average change from baseline across all available visits during the 6-month double-blind treatment period regardless of whether or not a patient was actually taking IP at that visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and post treatment

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	152	147	154	153
Units: liters				
least squares mean (standard error)	0 (± 0.029)	0.03 (± 0.029)	0.04 (± 0.028)	0 (± 0.029)

### Statistical analyses

Statistical analysis title	FEV1 post-bronchodilator
----------------------------	--------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 5mg v Placebo
-------------------	------------------------

Number of subjects included in analysis	305
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.948
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.04
upper limit	0.05

<b>Statistical analysis title</b>	FEV1 post-bronchodilator
-----------------------------------	--------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.334
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.03
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.02
upper limit	0.07

<b>Statistical analysis title</b>	FEV1 post-bronchodilator
-----------------------------------	--------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	307
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.192
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.04

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.01
upper limit	0.08

## Secondary: Asthma control questionnaire [ACQ-5] score change from baseline to treatment period

End point title	Asthma control questionnaire [ACQ-5] score change from baseline to treatment period
-----------------	---

End point description:

Treatment period is defined as the average of all available scores during the 6-month double-blind treatment period regardless of whether or not a patient was actually taking IP at that visit (excluding any unscheduled visits): the planned visits for completion were 1 month (visit 6), 2 months (visit 7), 3 months (visit 8), 4 months (visit 9) and 6 months (visit 11)

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and post treatment

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	149	149	154	156
Units: score				
least squares mean (standard error)	-0.64 ( $\pm$ 0.097)	-0.66 ( $\pm$ 0.095)	-0.68 ( $\pm$ 0.094)	-0.7 ( $\pm$ 0.093)

## Statistical analyses

Statistical analysis title	Asthma control questionnaire
----------------------------	------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and baseline score included in the model. Negative values for a difference show AZD5069 to have a favourable outcome compared to placebo.

Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	305
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.476
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.07

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.09
upper limit	0.22

<b>Statistical analysis title</b>	Asthma control questionnaire
-----------------------------------	------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and baseline score included in the model. Negative values for a difference show AZD5069 to have a favourable outcome compared to placebo.

Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	305
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.678
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.04
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.11
upper limit	0.19

<b>Statistical analysis title</b>	Asthma control questionnaire
-----------------------------------	------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and baseline score included in the model. Negative values for a difference show AZD5069 to have a favourable outcome compared to placebo.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	310
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.766
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.03
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.12
upper limit	0.18

## Secondary: Asthma quality of life questionnaire (AQLQ[s]) overall and domain

**scores change from baseline to treatment period**

End point title	Asthma quality of life questionnaire (AQLQ[s]) overall and domain scores change from baseline to treatment period
-----------------	---

End point description:

Treatment period is defined as the average of all available scores during the 6-month double-blind treatment period regardless of whether or not a patient was actually taking IP at that visit (excluding any unscheduled visits): the planned visits for completion were 1 month (visit 6), 3 months (visit 8) and 6 months (visit 11).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and post treatment

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	145	145	152	153
Units: score				
least squares mean (standard error)				
overall score	0.52 (± 0.091)	0.46 (± 0.089)	0.5 (± 0.088)	0.52 (± 0.089)
Symptoms	0.63 (± 0.098)	0.61 (± 0.096)	0.65 (± 0.095)	0.62 (± 0.096)
Activity limitation	0.47 (± 0.093)	0.39 (± 0.091)	0.46 (± 0.09)	0.49 (± 0.091)
Emotional function	0.42 (± 0.106)	0.36 (± 0.104)	0.4 (± 0.103)	0.41 (± 0.104)

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Percentage of symptom-free days (eDiary) change from baseline to post-randomisation periods**

End point title	Percentage of symptom-free days (eDiary) change from baseline to post-randomisation periods
-----------------	---

End point description:

Treatment Period is defined as the percentage of symptom-free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day)

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Day1 to Day 28

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	160	159
Units: percent				
least squares mean (standard error)	1.2 (± 1.91)	1.6 (± 1.87)	-0.4 (± 1.85)	1.1 (± 1.84)



## Statistical analyses

<b>Statistical analysis title</b>	Percentage of symptom-free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.974
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.9
upper limit	3.1

<b>Statistical analysis title</b>	Percentage of symptom-free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.797
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.5
upper limit	3.5

<b>Statistical analysis title</b>	Percentage of symptom-free days
-----------------------------------	---------------------------------

**Statistical analysis description:**

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	319
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.419
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.5
upper limit	1.5

### Secondary: Percentage of symptom-free days (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of symptom-free days (eDiary) change from baseline to post-randomisation periods
-----------------	---

**End point description:**

Treatment Period is defined as the percentage of symptom-free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day)

End point type	Secondary
----------------	-----------

**End point timeframe:**

Baselien and Day 29 to Day 56

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	152	148	158	155
Units: percent				
least squares mean (standard error)	3.4 (± 2.81)	2.6 (± 2.75)	0.2 (± 2.73)	3.1 (± 2.73)

**Statistical analyses**

<b>Statistical analysis title</b>	Percentage of symptom-free days
-----------------------------------	---------------------------------

**Statistical analysis description:**

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 5mg v Placebo
-------------------	------------------------

Number of subjects included in analysis	307
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.906
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.1
upper limit	4.7

<b>Statistical analysis title</b>	Percentage of symptom-free days
-----------------------------------	---------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	303
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.83
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5
upper limit	3.8

<b>Statistical analysis title</b>	Percentage of symptom-free days
-----------------------------------	---------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	313
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.266
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.9

Confidence interval	
level	90 %
sides	2-sided
lower limit	-7.3
upper limit	1.4

## Secondary: Percentage of symptom-free days (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of symptom-free days (eDiary) change from baseline to post-randomisation periods
-----------------	---

End point description:

Treatment Period is defined as the percentage of symptom-free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day)

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Day 57 to Day 84

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	149	146	155	154
Units: percent				
least squares mean (standard error)	3 (± 3.05)	4.3 (± 2.99)	1.4 (± 2.96)	4 (± 2.96)

## Statistical analyses

Statistical analysis title	Percentage of symptom-free days
----------------------------	---------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	303
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.725
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.8
upper limit	3.8

<b>Statistical analysis title</b>	Percentage of symptom-free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.904
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.4
upper limit	5.1

<b>Statistical analysis title</b>	Percentage of symptom-free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	309
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.374
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-7.3
upper limit	2.2

## **Secondary: Percentage of symptom-free days (eDiary) change from baseline to post-randomisation periods**

End point title	Percentage of symptom-free days (eDiary) change from baseline to post-randomisation periods
-----------------	---

End point description:

Treatment Period is defined as the percentage of symptom-free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available

within the treatment period regardless of whether or not a patient was actually taking IP on that day)

End point type	Secondary
End point timeframe:	
Baseline and Day 85 to End of 6 Months	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	148	145	152	151
Units: percent				
least squares mean (standard error)	3.9 ( $\pm$ 3.17)	5.6 ( $\pm$ 3.11)	2.6 ( $\pm$ 3.11)	4.4 ( $\pm$ 3.09)

### Statistical analyses

Statistical analysis title	Percentage of symptom-free days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	299
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.884
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.4
upper limit	4.5

Statistical analysis title	Percentage of symptom-free days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	296
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.688
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.2

Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.8
upper limit	6.2

<b>Statistical analysis title</b>	Percentage of symptom-free days
-----------------------------------	---------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	303
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.557
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.7
upper limit	3.2

## Secondary: Percentage of symptom-free days (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of symptom-free days (eDiary) change from baseline to post-randomisation periods
-----------------	---

End point description:

Treatment Period is defined as the percentage of symptom-free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day)

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and treatment period

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	160	159
Units: percent				
least squares mean (standard error)	3.7 (± 2.61)	4.2 (± 2.56)	1.4 (± 2.53)	3.3 (± 2.53)

## Statistical analyses

Statistical analysis title	Percentage of symptom-free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.885
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.8
upper limit	4.5

Statistical analysis title	Percentage of symptom-free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.721
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.2
upper limit	5

Statistical analysis title	Percentage of symptom-free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD5069 45mg v Placebo



Number of subjects included in analysis	319
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.444
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6
upper limit	2.2

## Secondary: Percentage of asthma-control days (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of asthma-control days (eDiary) change from baseline to post-randomisation periods
End point description:	
Treatment Period is defined as the percentage of symptom-free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day).	
End point type	Secondary
End point timeframe:	
Baseline and Day 1 to Day 28	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	160	159
Units: percent				
least squares mean (standard error)	1.2 (± 1.74)	1.7 (± 1.71)	-1.1 (± 1.68)	0.9 (± 1.68)

## Statistical analyses

Statistical analysis title	Percentage of asthma-control days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo

Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.87
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.5
upper limit	3

<b>Statistical analysis title</b>	Percentage of asthma-control days
-----------------------------------	-----------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.625
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.9
upper limit	3.6

<b>Statistical analysis title</b>	Percentage of asthma-control days
-----------------------------------	-----------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	319
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.214
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.1

Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.8
upper limit	0.7

## Secondary: Percentage of asthma-control days (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of asthma-control days (eDiary) change from baseline to post-randomisation periods
-----------------	---

End point description:

Treatment Period is defined as the percentage of symptom-free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Day 29 to Day 56

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	151	148	158	155
Units: percent				
least squares mean (standard error)	2.7 (± 2.59)	3.5 (± 2.54)	-0.1 (± 2.51)	2.8 (± 2.52)

## Statistical analyses

Statistical analysis title	Percentage of asthma-control days
----------------------------	-----------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	306
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.982
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.1
upper limit	4

<b>Statistical analysis title</b>	Percentage of asthma-control days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	303
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.764
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.3
upper limit	4.8

<b>Statistical analysis title</b>	Percentage of asthma-control days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	313
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.239
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.9
upper limit	1.1

## **Secondary: Percentage of asthma-control days (eDiary) change from baseline to post-randomisation periods**

End point title	Percentage of asthma-control days (eDiary) change from baseline to post-randomisation periods
-----------------	---

End point description:

Treatment Period is defined as the percentage of symptom-free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available

within the treatment period regardless of whether or not a patient was actually taking IP on that day).

End point type	Secondary
End point timeframe:	
Baseline and Day 57 to Day 84	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	149	146	155	154
Units: percent				
least squares mean (standard error)	3.2 ( $\pm$ 2.92)	4.7 ( $\pm$ 2.87)	0.9 ( $\pm$ 2.84)	2.9 ( $\pm$ 2.84)

### Statistical analyses

Statistical analysis title	Percentage of asthma-control days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	303
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.904
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.2
upper limit	4.9

Statistical analysis title	Percentage of asthma-control days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.519
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.8
upper limit	6.4

<b>Statistical analysis title</b>	Percentage of asthma-control days
-----------------------------------	-----------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	309
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.466
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.6
upper limit	2.5

### **Secondary: Percentage of asthma-control days (eDiary) change from baseline to post-randomisation periods**

End point title	Percentage of asthma-control days (eDiary) change from baseline to post-randomisation periods
-----------------	---

End point description:

Treatment Period is defined as the percentage of symptom-free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day).

End point type	Secondary
----------------	-----------

End point timeframe:

Bseline and Day 85 to End of 6 Months

<b>End point values</b>	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	148	145	152	151
Units: percent				
least squares mean (standard error)	3.9 ( $\pm$ 2.99)	5.7 ( $\pm$ 2.93)	1.4 ( $\pm$ 2.93)	2.4 ( $\pm$ 2.91)

## Statistical analyses

<b>Statistical analysis title</b>	Percentage of asthma-control days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	299
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.604
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.2
upper limit	6.1

<b>Statistical analysis title</b>	Percentage of asthma-control days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	296
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.256
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	3.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.5
upper limit	7.9

<b>Statistical analysis title</b>	Percentage of asthma-control days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	303
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.71
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.7
upper limit	3.6

### Secondary: Percentage of asthma-control days (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of asthma-control days (eDiary) change from baseline to post-randomisation periods
End point description: Treatment Period is defined as the percentage of symptom-free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day).	
End point type	Secondary
End point timeframe: Baseline and Treatment Period	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	160	159
Units: percent				
least squares mean (standard error)	3.5 (± 2.46)	4.4 (± 2.42)	0.6 (± 2.38)	2.3 (± 2.38)

### Statistical analyses

<b>Statistical analysis title</b>	Percentage of asthma-control days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo



Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.605
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.7
upper limit	5.1

<b>Statistical analysis title</b>	Percentage of asthma-control days
-----------------------------------	-----------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.359
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	2.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.7
upper limit	6.1

<b>Statistical analysis title</b>	Percentage of asthma-control days
-----------------------------------	-----------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	319
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.475
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.7

Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.5
upper limit	2.2

## Secondary: Percentage of rescue medication free days (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of rescue medication free days (eDiary) change from baseline to post-randomisation periods
-----------------	---

End point description:

Treatment Period is defined as the percentage of rescue medication free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Day 1 to Day 28

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	160	159
Units: percent				
least squares mean (standard error)	6.8 (± 2.89)	8.3 (± 2.84)	4 (± 2.79)	9.5 (± 2.8)

## Statistical analyses

Statistical analysis title	Percentage of rescue medication free days
----------------------------	---

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.324
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-7.3
upper limit	1.8

<b>Statistical analysis title</b>	Percentage of rescue medication free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.664
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.8
upper limit	3.4

<b>Statistical analysis title</b>	Percentage of rescue medication free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	319
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.047
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-5.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10
upper limit	-1

## Secondary: Percentage of rescue medication free days (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of rescue medication free days (eDiary) change from baseline to post-randomisation periods
-----------------	---

End point description:

Treatment Period is defined as the percentage of rescue medication free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was

available within the treatment period regardless of whether or not a patient was actually taking IP on that day).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Day 29 to Day 56

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	150	148	158	155
Units: percent				
least squares mean (standard error)	15.4 (± 3.84)	17.6 (± 3.76)	10.7 (± 3.71)	9.5 (± 2.8)

## Statistical analyses

<b>Statistical analysis title</b>	Percentage of rescue medication free days
-----------------------------------	---

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	305
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.791
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-7
upper limit	5

<b>Statistical analysis title</b>	Percentage of rescue medication free days
-----------------------------------	---

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 15 mg v Placebo
-------------------	--------------------------

Number of subjects included in analysis	303
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.752
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.9
upper limit	7.2

<b>Statistical analysis title</b>	Percentage of rescue medication free days
-----------------------------------	---

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	313
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.114
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-5.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.6
upper limit	0.2

### **Secondary: Percentage of rescue medication free days (eDiary) change from baseline to post-randomisation periods**

End point title	Percentage of rescue medication free days (eDiary) change from baseline to post-randomisation periods
-----------------	---

End point description:

Treatment Period is defined as the percentage of rescue medication free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Day 57 to Day 84

<b>End point values</b>	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	147	146	155	153
Units: percent				
least squares mean (standard error)	19.8 ( $\pm$ 4.12)	19.2 ( $\pm$ 4.03)	12.3 ( $\pm$ 3.98)	18.7 ( $\pm$ 3.99)

## Statistical analyses

<b>Statistical analysis title</b>	Percentage of rescue medication free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.779
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.4
upper limit	7.6

<b>Statistical analysis title</b>	Percentage of rescue medication free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	299
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.896
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6
upper limit	7

<b>Statistical analysis title</b>	Percentage of rescue medication free days
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	308
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.099
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-6.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.8
upper limit	0

### Secondary: Percentage of rescue medication free days (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of rescue medication free days (eDiary) change from baseline to post-randomisation periods
End point description: Treatment Period is defined as the percentage of rescue medication free days across the entire 6-month double-blind treatment period for a patient (out of the total number number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day).	
End point type	Secondary
End point timeframe: Baseline and Day 85 to End of 6 Months	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	147	145	152	150
Units: percent				
least squares mean (standard error)	21.2 (± 4.25)	23.1 (± 4.16)	15.8 (± 4.16)	20 (± 4.14)

## Statistical analyses

<b>Statistical analysis title</b>	Percentage of rescue medication free days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	297
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.767
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.5
upper limit	7.8

<b>Statistical analysis title</b>	Percentage of rescue medication free days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	295
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.445
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.6
upper limit	9.8

<b>Statistical analysis title</b>	Percentage of rescue medication free days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD5069 45mg v Placebo



Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.298
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-4.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.8
upper limit	2.4

### Secondary: Percentage of rescue medication free days (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of rescue medication free days (eDiary) change from baseline to post-randomisation periods
End point description:	
Treatment Period is defined as the percentage of rescue medication free days across the entire 6-month double-blind treatment period for a patient (out of the total number of days where data was available within the treatment period regardless of whether or not a patient was actually taking IP on that day).	
End point type	Secondary
End point timeframe:	
Baseline and Treatment Period	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	160	159
Units: percent				
least squares mean (standard error)	16.6 (± 3.58)	18.1 (± 3.51)	11.5 (± 3.46)	16.7 (± 3.46)

### Statistical analyses

Statistical analysis title	Percentage of rescue medication free days
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo

Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.969
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.8
upper limit	5.5

<b>Statistical analysis title</b>	Percentage of rescue medication free days
-----------------------------------	---

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	1.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.3
upper limit	7

<b>Statistical analysis title</b>	Percentage of rescue medication free days
-----------------------------------	---

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	319
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.124
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-5.2

Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.9
upper limit	0.4

## Secondary: Percentage of night-time awakenings due to asthma symptoms (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of night-time awakenings due to asthma symptoms (eDiary) change from baseline to post-randomisation periods
End point description: Treatment Period is defined as the percentage of night-time awakenings due to asthma symptoms across the entire 6-month double-blind treatment period for a patient (out of the total number of days where data was available within the treatment period, regardless of whether or not a patient was actually taking IP on that day).	
End point type	Secondary
End point timeframe: Baseline and Day 1 to Day 28	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	153	161	159
Units: percent				
least squares mean (standard error)	-11.3 (± 2.85)	-11.1 (± 2.8)	-10.1 (± 2.75)	-8.9 (± 2.76)

## Statistical analyses

Statistical analysis title	Percentage of night-time awakenings
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	315
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.375
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.9
upper limit	2.1

<b>Statistical analysis title</b>	Percentage of night-time awakenings
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.424
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.7
upper limit	2.3

<b>Statistical analysis title</b>	Percentage of night-time awakenings
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	320
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.663
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.6
upper limit	3.3

## **Secondary: Percentage of night-time awakenings due to asthma symptoms (eDiary) change from baseline to post-randomisation periods**

End point title	Percentage of night-time awakenings due to asthma symptoms (eDiary) change from baseline to post-randomisation periods
-----------------	--

End point description:

Treatment Period is defined as the percentage of night-time awakenings due to asthma symptoms across the entire 6-month double-blind treatment period for a patient (out of the total number of days

where data was available within the treatment period, regardless of whether or not a patient was actually taking IP on that day).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Day 29 to Day 56

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	152	148	158	156
Units: percent				
least squares mean (standard error)	-18.2 (± 3.41)	-19 (± 3.35)	-15.2 (± 3.31)	-15.2 (± 3.32)

## Statistical analyses

Statistical analysis title	Percentage of night-time awakenings
----------------------------	-------------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	308
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.359
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.3
upper limit	2.4

Statistical analysis title	Percentage of night-time awakenings
----------------------------	-------------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 15 mg v Placebo
-------------------	--------------------------

Number of subjects included in analysis	304
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.244
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-3.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.2
upper limit	1.6

<b>Statistical analysis title</b>	Percentage of night-time awakenings
-----------------------------------	-------------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	314
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.995
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.3
upper limit	5.3

### **Secondary: Percentage of night-time awakenings due to asthma symptoms (eDiary) change from baseline to post-randomisation periods**

End point title	Percentage of night-time awakenings due to asthma symptoms (eDiary) change from baseline to post-randomisation periods
-----------------	--

End point description:

Treatment Period is defined as the percentage of night-time awakenings due to asthma symptoms across the entire 6-month double-blind treatment period for a patient (out of the total number of days where data was available within the treatment period, regardless of whether or not a patient was actually taking IP on that day).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Day 57 to Day 84

<b>End point values</b>	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	149	146	155	154
Units: percent				
least squares mean (standard error)	-22.1 ( $\pm$ 3.55)	-19.8 ( $\pm$ 3.48)	-17.6 ( $\pm$ 3.44)	-16.7 ( $\pm$ 3.45)

## Statistical analyses

<b>Statistical analysis title</b>	Percentage of night-time awakenings
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	303
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.111
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-5.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.9
upper limit	0.2

<b>Statistical analysis title</b>	Percentage of night-time awakenings
Statistical analysis description:	
Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.365
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.7
upper limit	2.5

<b>Statistical analysis title</b>	Percentage of night-time awakenings
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	
Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	309
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.793
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.4
upper limit	4.6

### Secondary: Percentage of night-time awakenings due to asthma symptoms (eDiary) change from baseline to post-randomisation periods

End point title	Percentage of night-time awakenings due to asthma symptoms (eDiary) change from baseline to post-randomisation periods
End point description: Treatment Period is defined as the percentage of night-time awakenings due to asthma symptoms across the entire 6-month double-blind treatment period for a patient (out of the total number of days where data was available within the treatment period, regardless of whether or not a patient was actually taking IP on that day).	
End point type	Secondary
End point timeframe: Baseline and Day 85 to End of 6 Months	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	148	145	153	152
Units: percent				
least squares mean (standard error)	-25.3 (± 3.64)	-25.5 (± 3.56)	-22.8 (± 3.09)	-21.8 (± 3.54)

### Statistical analyses

<b>Statistical analysis title</b>	Percentage of night-time awakenings
Statistical analysis description: Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.	



Comparison groups	AZD 5069 5mg v Placebo
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.318
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-3.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.1
upper limit	2.2

<b>Statistical analysis title</b>	Percentage of night-time awakenings
-----------------------------------	-------------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD 5069 15 mg v Placebo
Number of subjects included in analysis	297
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.297
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-3.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.3
upper limit	2.1

<b>Statistical analysis title</b>	Percentage of night-time awakenings
-----------------------------------	-------------------------------------

Statistical analysis description:

Statistical analysis is based on an ANCOVA model with treatment, OCS use at baseline (yes or no) and derived baseline value included in the model.

Comparison groups	AZD5069 45mg v Placebo
Number of subjects included in analysis	305
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.776
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1

Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.6
upper limit	4.6

### Secondary: Uncontrolled asthma weeks based on eDiary

End point title	Uncontrolled asthma weeks based on eDiary
End point description:	
An uncontrolled asthma week is defined as the fulfilment of 1 of the following conditions: 1) two consecutive days with awakenings due to asthma on both nights and 2) a recorded use of rescue medication for symptom relief on at least 3 occasions per day, for 2 consecutive days (where one occasion is defined as one puff of rescue medication). Baseline is defined as the last 2 weeks (14 days) before randomisation for each patient.	
End point type	Secondary
End point timeframe:	
Baseline and 6 months treatment period	

End point values	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	153	151	157	157
Units: weeks				
arithmetic mean (standard deviation)	10.4 (± 9.84)	10.7 (± 10.02)	11 (± 10)	10.9 (± 9.89)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Well-controlled asthma weeks based on eDiary

End point title	Well-controlled asthma weeks based on eDiary
End point description:	
A well-controlled asthma week is defined as the fulfilment of both conditions: 1) no night-time awakenings due to asthma symptoms and no severe or mild/moderate asthma exacerbations and 2) two or more of the following 3 criteria are fulfilled: a) asthma symptoms on no more than 2 days with a daytime symptom score of >1, b) no more than 2 days of rescue medication use, up to a maximum of 4 occasions per week (where one occasion is defined as one puff of rescue medication) and c) $\geq 80\%$ of predicted normal(PN) morning PEF every day (according to the ERS guidelines).	
End point type	Secondary
End point timeframe:	
Baseline and 6 months treatment period	

<b>End point values</b>	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	154	151	157	158
Units: weeks				
arithmetic mean (standard deviation)	2.4 ( $\pm$ 5.38)	1.9 ( $\pm$ 4.78)	1.7 ( $\pm$ 4.38)	2.3 ( $\pm$ 5.27)

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Safety evaluations were performed for the 12 months of the study. 6-month results would be reported.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

### Reporting groups

Reporting group title	AZD 5069 5mg
-----------------------	--------------

Reporting group description: -

Reporting group title	AZD 5069 15 mg
-----------------------	----------------

Reporting group description: -

Reporting group title	AZD5069 45mg
-----------------------	--------------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 156 (4.49%)	8 / 153 (5.23%)	14 / 161 (8.70%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
RENAL CANCER			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUNG NEOPLASM MALIGNANT			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UTERINE LEIOMYOMA			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			

PERIPHERAL EMBOLISM			
subjects affected / exposed	1 / 156 (0.64%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSION			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
OVARIAN CYST			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
ASTHMA			
subjects affected / exposed	4 / 156 (2.56%)	3 / 153 (1.96%)	4 / 161 (2.48%)
occurrences causally related to treatment / all	1 / 4	0 / 4	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASTHMATIC CRISIS			
subjects affected / exposed	0 / 156 (0.00%)	1 / 153 (0.65%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 156 (0.00%)	1 / 153 (0.65%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
PATELLA FRACTURE			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			

PSEUDOHYPOPARATHYROIDISM			
subjects affected / exposed	1 / 156 (0.64%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ATRIAL FIBRILLATION			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CORONARY ARTERY DISEASE			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
CRITICAL ILLNESS			
POLYNEUROPATHY			
subjects affected / exposed	0 / 156 (0.00%)	1 / 153 (0.65%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ISCHAEMIC STROKE			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
NEUTROPENIA			
subjects affected / exposed	0 / 156 (0.00%)	1 / 153 (0.65%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
BARRETTS OESOPHAGUS			
subjects affected / exposed	0 / 156 (0.00%)	1 / 153 (0.65%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTRITIS			

subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIATUS HERNIA			
subjects affected / exposed	0 / 156 (0.00%)	1 / 153 (0.65%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL HERNIA			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INGUINAL HERNIA			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
CHOLECYSTITIS CHRONIC			
subjects affected / exposed	1 / 156 (0.64%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLELITHIASIS			
subjects affected / exposed	0 / 156 (0.00%)	1 / 153 (0.65%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
CALCULUS URETERIC			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 156 (0.00%)	1 / 153 (0.65%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations PNEUMONIA subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 156 (0.00%) 0 / 0 0 / 0	1 / 153 (0.65%) 0 / 1 0 / 0	3 / 161 (1.86%) 0 / 4 0 / 0
ABDOMINAL ABSCESS subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 156 (0.00%) 0 / 0 0 / 0	0 / 153 (0.00%) 0 / 0 0 / 0	1 / 161 (0.62%) 0 / 1 0 / 0
HELICOBACTER GASTRITIS subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 156 (0.00%) 0 / 0 0 / 0	1 / 153 (0.65%) 0 / 1 0 / 0	0 / 161 (0.00%) 0 / 0 0 / 0
LOWER RESPIRATORY TRACT INFECTION subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 156 (0.00%) 0 / 0 0 / 0	0 / 153 (0.00%) 0 / 0 0 / 0	1 / 161 (0.62%) 1 / 1 0 / 0
LOWER RESPIRATORY TRACT INFECTION BACTERIAL subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 156 (0.64%) 0 / 1 0 / 0	0 / 153 (0.00%) 0 / 0 0 / 0	0 / 161 (0.00%) 0 / 0 0 / 0
SALMONELLOSIS subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 156 (0.00%) 0 / 0 0 / 0	1 / 153 (0.65%) 0 / 1 0 / 0	0 / 161 (0.00%) 0 / 0 0 / 0
STREPTOCOCCAL SEPSIS subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 156 (0.00%) 0 / 0 0 / 0	1 / 153 (0.65%) 0 / 1 0 / 0	0 / 161 (0.00%) 0 / 0 0 / 0
VIRAL UPPER RESPIRATORY TRACT INFECTION			



subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	1 / 161 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>ACUTE TONSILLITIS</b>			
subjects affected / exposed	0 / 156 (0.00%)	0 / 153 (0.00%)	0 / 161 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Placebo		
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 159 (8.18%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
<b>RENAL CANCER</b>			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>LUNG NEOPLASM MALIGNANT</b>			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>UTERINE LEIOMYOMA</b>			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
<b>PERIPHERAL EMBOLISM</b>			
subjects affected / exposed	0 / 159 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>HYPERTENSION</b>			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
OVARIAN CYST			
subjects affected / exposed	0 / 159 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
ASTHMA			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
ASTHMATIC CRISIS			
subjects affected / exposed	0 / 159 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
PATELLA FRACTURE			
subjects affected / exposed	0 / 159 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
PSEUDOHYPOPARATHYROIDISM			
subjects affected / exposed	0 / 159 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			

<b>ATRIAL FIBRILLATION</b> subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 159 (0.63%) 0 / 1 0 / 0		
<b>CORONARY ARTERY DISEASE</b> subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 159 (0.63%) 0 / 1 0 / 0		
<b>Nervous system disorders</b> <b>CRITICAL ILLNESS</b> <b>POLYNEUROPATHY</b> subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 159 (0.00%) 0 / 0 0 / 0		
<b>ISCHAEMIC STROKE</b> subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 159 (0.63%) 0 / 1 0 / 0		
<b>Blood and lymphatic system disorders</b> <b>NEUTROPENIA</b> subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 159 (0.00%) 0 / 0 0 / 0		
<b>Gastrointestinal disorders</b> <b>BARRETTS OESOPHAGUS</b> subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 159 (0.00%) 0 / 0 0 / 0		
<b>GASTRITIS</b> subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 159 (0.00%) 0 / 0 0 / 0		
<b>HIATUS HERNIA</b>			

subjects affected / exposed	0 / 159 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ABDOMINAL HERNIA			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
INGUINAL HERNIA			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
CHOLECYSTITIS CHRONIC			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CHOLELITHIASIS			
subjects affected / exposed	0 / 159 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
CALCULUS URETERIC			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 159 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
PNEUMONIA			

subjects affected / exposed	2 / 159 (1.26%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
ABDOMINAL ABSCESS				
subjects affected / exposed	0 / 159 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
HELICOBACTER GASTRITIS				
subjects affected / exposed	0 / 159 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LOWER RESPIRATORY TRACT INFECTION				
subjects affected / exposed	0 / 159 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LOWER RESPIRATORY TRACT INFECTION BACTERIAL				
subjects affected / exposed	0 / 159 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SALMONELLOSIS				
subjects affected / exposed	0 / 159 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
STREPTOCOCCAL SEPSIS				
subjects affected / exposed	0 / 159 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
VIRAL UPPER RESPIRATORY TRACT INFECTION				
subjects affected / exposed	0 / 159 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ACUTE TONSILLITIS				

subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 1 %

<b>Non-serious adverse events</b>	AZD 5069 5mg	AZD 5069 15 mg	AZD5069 45mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	67 / 156 (42.95%)	60 / 153 (39.22%)	72 / 161 (44.72%)
Nervous system disorders			
HEADACHE			
subjects affected / exposed	6 / 156 (3.85%)	12 / 153 (7.84%)	12 / 161 (7.45%)
occurrences (all)	6	12	12
Gastrointestinal disorders			
ABDOMINAL PAIN UPPER			
subjects affected / exposed	4 / 156 (2.56%)	4 / 153 (2.61%)	2 / 161 (1.24%)
occurrences (all)	4	4	2
NAUSEA			
subjects affected / exposed	2 / 156 (1.28%)	3 / 153 (1.96%)	3 / 161 (1.86%)
occurrences (all)	2	3	3
DIARRHOEA			
subjects affected / exposed	2 / 156 (1.28%)	0 / 153 (0.00%)	4 / 161 (2.48%)
occurrences (all)	2	0	4
GASTROESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	1 / 156 (0.64%)	0 / 153 (0.00%)	4 / 161 (2.48%)
occurrences (all)	1	0	4
Respiratory, thoracic and mediastinal disorders			
ASTHMA			
subjects affected / exposed	4 / 156 (2.56%)	3 / 153 (1.96%)	4 / 161 (2.48%)
occurrences (all)	4	3	4
COUGH			
subjects affected / exposed	3 / 156 (1.92%)	2 / 153 (1.31%)	1 / 161 (0.62%)
occurrences (all)	3	2	1
Musculoskeletal and connective tissue disorders			

BACK PAIN			
subjects affected / exposed	1 / 156 (0.64%)	4 / 153 (2.61%)	2 / 161 (1.24%)
occurrences (all)	1	4	2
ARTHRALGIA			
subjects affected / exposed	2 / 156 (1.28%)	2 / 153 (1.31%)	1 / 161 (0.62%)
occurrences (all)	2	2	1
Infections and infestations			
NASOPHARYNGITIS			
subjects affected / exposed	18 / 156 (11.54%)	13 / 153 (8.50%)	18 / 161 (11.18%)
occurrences (all)	18	13	18
BRONCHITIS			
subjects affected / exposed	1 / 156 (0.64%)	6 / 153 (3.92%)	7 / 161 (4.35%)
occurrences (all)	1	6	7
PHARYNGITIS			
subjects affected / exposed	5 / 156 (3.21%)	4 / 153 (2.61%)	3 / 161 (1.86%)
occurrences (all)	5	4	3
VIRAL UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	3 / 156 (1.92%)	3 / 153 (1.96%)	6 / 161 (3.73%)
occurrences (all)	3	3	6
INFLUENZA			
subjects affected / exposed	4 / 156 (2.56%)	3 / 153 (1.96%)	3 / 161 (1.86%)
occurrences (all)	4	3	3
PNEUMONIA			
subjects affected / exposed	1 / 156 (0.64%)	2 / 153 (1.31%)	4 / 161 (2.48%)
occurrences (all)	1	2	4
RHINITIS			
subjects affected / exposed	1 / 156 (0.64%)	4 / 153 (2.61%)	2 / 161 (1.24%)
occurrences (all)	1	4	2
SINUSITIS			
subjects affected / exposed	3 / 156 (1.92%)	1 / 153 (0.65%)	3 / 161 (1.86%)
occurrences (all)	3	1	3
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 156 (0.64%)	1 / 153 (0.65%)	4 / 161 (2.48%)
occurrences (all)	1	1	4
URINARY TRACT INFECTION			

subjects affected / exposed	0 / 156 (0.00%)	3 / 153 (1.96%)	3 / 161 (1.86%)
occurrences (all)	0	3	3
<b>GASTROENTERITIS</b>			
subjects affected / exposed	1 / 156 (0.64%)	2 / 153 (1.31%)	1 / 161 (0.62%)
occurrences (all)	1	2	1
<b>UPPER RESPIRATORY TRACT INFECTION</b>			
subjects affected / exposed	6 / 156 (3.85%)	2 / 153 (1.31%)	3 / 161 (1.86%)
occurrences (all)	6	2	3

<b>Non-serious adverse events</b>	Placebo		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	83 / 159 (52.20%)		
<b>Nervous system disorders</b>			
<b>HEADACHE</b>			
subjects affected / exposed	15 / 159 (9.43%)		
occurrences (all)	15		
<b>Gastrointestinal disorders</b>			
<b>ABDOMINAL PAIN UPPER</b>			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
<b>NAUSEA</b>			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
<b>DIARRHOEA</b>			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
<b>GASTROOESOPHAGEAL REFLUX DISEASE</b>			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>ASTHMA</b>			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
<b>COUGH</b>			



subjects affected / exposed occurrences (all)	0 / 159 (0.00%) 0		
Musculoskeletal and connective tissue disorders			
BACK PAIN			
subjects affected / exposed	6 / 159 (3.77%)		
occurrences (all)	6		
ARTHRALGIA			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Infections and infestations			
NASOPHARYNGITIS			
subjects affected / exposed	31 / 159 (19.50%)		
occurrences (all)	31		
BRONCHITIS			
subjects affected / exposed	10 / 159 (6.29%)		
occurrences (all)	10		
PHARYNGITIS			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	5		
VIRAL UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
INFLUENZA			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
PNEUMONIA			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
RHINITIS			
subjects affected / exposed	0 / 159 (0.00%)		
occurrences (all)	0		
SINUSITIS			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	5		
LOWER RESPIRATORY TRACT INFECTION			

subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
URINARY TRACT INFECTION			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
GASTROENTERITIS			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 October 2012	Clarification regarding the use of contraception during the study after new in vitro results became available. Clarification that patients were to contact the investigator regarding increased body temperatures and for worsening of asthma signs.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported